The oxidative phosphorylation system (OXPHOS) is organized into ve multi-protein complexes, comprising four complexes (I-IV) of the respiratory chain and ATP synthase (complex V). OXPHOS has a vital role in cellular energy metabolism and ATP production. Enzyme analysis of individual OXPHOS complexes in a skeletal muscle biopsy remains the mainstay of the diagnostic process for patients suspected of mitochondrial cytopathy. Practical guidelines are presented to provide optimal conditions for performance of laboratory investigations and a reliable diagnosis. A fresh muscle biopsy is preferable to a frozen muscle sample because the overall capacity of the OXPHOS system can be measured in a fresh biopsy. In about 25% of patients referred for muscle biopsy to our centre, reduced substrate oxidation rates and ATP+creatine phosphate production rates were found without any defect in complexes I-V and the pyruvate dehydrogenase complex. Investigation of frozen muscle biopsy alone may lead to false-negative diagnoses in many patients. In some patients, it is necessary to investigate broblasts for prospective diagnostic purposes. An exact diagnosis of respiratory chain defects is a prerequisite for rational therapy and genetic counselling. Provided guidelines for specimen collection are followed, there are now reliable methods for identifying respiratory chain defects.
Mitochondria are cytoplasmic cell organelles in which the energy-rich compounds ATP and creatine phosphate (CrP) are synthesized (see Fig. 1 ). During glycolysis, pyruvate is produced from glucose in the cytoplasm of the cell. Under anaerobic conditions, pyruvate is converted into lactate by lactate dehydrogenase (LDH). Under aerobic conditions, pyruvate is transported into the mitochondria, where it is converted into acetyl-coenzyme A (CoA) by the pyruvate dehydrogenase (PDH) complex. Acetyl-CoA is also formed from fatty acids by b-oxidation. The PDH complex is regulated by two enzymes: pyruvate dehydrogenase phosphatase, which dephosphorylates the inactive E1-subunit of the complex, leading to activation; and pyruvate dehydrogenase kinase, which re-phosphorylates the active E1-subunit of the complex, leading to inactivation. The PDH complex is also regulated by the NADH/NAD + ratio and the acetyl-CoA/CoA ratio. Increases of these ratios result in feedback inhibition of the PDH complex. Acetyl-CoA from pyruvate and fatty acids is also oxidized in the citric acid cycle. During the oxidation of pyruvate, fatty acids are produced and in the citric acid cycle NADH and FADH 2 are produced. These reduced coenzymes are oxidized to NAD + or FAD by complex I and complex II, respectively, of the mitochondrial respiratory chain. The electrons are transferred from complex I and complex II to the soluble redox carrier coenzyme Q10 and are further transported via complex III and cytochrome c to complex IV. In this ¢nal step, oxygen is reduced to H 2 O. The energy released during the electron transfer reactions is conserved in the form of an electrochemical proton gradient by the transport of protons across the mitochondrial inner membrane. At the level of complexV, the protons are transported back into the mitochondrion and the released energy is used to synthesize the energy-rich compounds ATP and creatine phosphate. The process by which Personal View oxidation of substrates by the mitochondrial respiratory chain is coupled to the phosphorylation of ADP into ATP is called oxidative phosphorylation.
Mitochondrial cytopathies are a group of disorders caused by defects in one or more of the enzymes involved in mitochondrial energy metabolism. These defects are frequently localized in the PDH complex and/or in one or more of the respiratory chain complexes.
What are the consequences of a defect in a respiratory chain complex?
A defect in one or more of the respiratory chain complexes results in a disturbed oxidation ratio of NADH to NAD + (in cases of complex I, III and IV defects) or a disturbance of the oxidation ratio of FADH 2 to FAD (in cases of complex II defects). Let us assume that a patient is su¡ering from an isolated complex I de¢ciency. This leads to an increase in NADH and decrease in NAD + . The increased NADH/ NAD + ratio exerts a feedback inhibition on the PDH complex, leading to an increase in mitochondrial pyruvate. Pyruvate is thereafter transported into the cytosol and further metabolized into lactate by LDH or converted into alanine by transamination. Therefore, the ¢nal result of a complex I de¢ciency is an intracellular increase of lactate, pyruvate and alanine with a concomitant increase of these metabolites in body £uids [blood and urine and frequently also in cerebrospinal £uid (CSF)].
Apart from an absolute increase in lactate and pyruvate concentrations, respiratory chain defects are also frequently associated with an increased ratio of lactate/pyruvate in blood and CSF. This phenomenon can be explained by a shift of the LDH-catalysed reaction in favour of lactate caused by the increased ratio of NADH/NAD + .
Clinical presentation
The clinical abnormalities in patients su¡ering from a mitochondrial disorder are very heterogeneous and often non-speci¢c. The symptomatology varies in age of onset (from birth to adulthood) and course (rapidly progressive or static). In some patients only one tissue seems to be a¡ected, whereas other patients seem to su¡er from a multisystem disorder.
In the majority of the patients, muscular and/or neurological complaints are the main presenting symptoms. Some symptoms are age-dependent (e.g. failure to thrive in neonates and exercise intolerance in adulthood); others (e.g. hypotonia, retardation) can present at any age. Many patients, particularly children, who meet the morphological, biochemical and/or molecular biological criteria for a mitochondrial disorder cannot be classi¢ed into one of the above entities. An additional complication is that, in a few patients, the clinical picture gradually changes from one well de¢ned clinical phenotype into another.
No single clinical feature is diagnostically speci¢c or distinctive. A patient is suspected to su¡er from a mitochondrial disorder if demonstrating at least two chronic and unexplained symptoms from the extended list in Table 1 , preferably occurring in two unrelated organs. 1, 2 
Initial biochemical investigations
Patients suspected of su¡ering from a mitochondrial cytopathy on clinical grounds should undergo the following initial biochemical investigations:
. Blood, urine and CSF lactate, pyruvate and alanine measurement, and calculation of the lactate/ pyruvate ratio in blood and CSF. 3, 4 . Measurement of urinary amino acids.
A generalized aminoaciduria may occur in respiratory chain defects due to the latter's e¡ect on the proximal tubular cells of the kidney, which leads to a decreased reabsorption of amino acids and thus increased excretion.
Analysis of organic acids in the urine may provide additional diagnostic information because, apart from lactate, citric acid cycle intermediates such as 2oxoglutarate, succinate, fumarate and malate may be excreted in increased amounts in the urine of patients with a respiratory chain defect. The ¢nding of a normal concentration of lactate in blood, urine and CSF does not always exclude a respiratory chain defect. Where there is a strong suspicion of such a defect on clinical grounds, a glucose tolerance test is recommended with simultaneous determination of blood lactate. 5 Under normal conditions, lactate concentrations in blood remain nearly constant or increase only slightly, but in a respiratory chain defect a pathological increase may occur.
De nite biochemical investigations

Muscle biopsy collection guidelines
To optimize the performance of biochemical investigations on a muscle biopsy, it is essential to follow the guidelines summarized in Table 2 . It is very important to obtain a muscle sample of su¤cient size, enabling the whole diagnostic programme to be performed. At least 300 mg of a fresh muscle sample is required. If a smaller amount of tissue is sent to our centre, the material cannot be handled as a fresh muscle sample, and the measurements of enzyme activities are limited. The quality of the biopsy is also important and should be critically evaluated before processing. The sample must be free of connective tissue and fatty tissue as far as possible. The specimen collection and transport conditions are critical. For fresh samples our rules are the following. The biopsy should be taken under general anaesthesia (needle biopsy using local anaesthesia with lidocaine should be avoided). The sample must be placed immediately in a vial containing ice-cold sucrose EDTA Tris-HCl (SETH) bu¡er, cooled by a su¤cient amount of melting ice and sent to the diagnostic laboratory by courier. For frozen samples, the biopsy must be frozen immediately in liquid nitrogen, without using isopentane, and should be transported in a vial that is placed in a su¤cient amount of dry ice to keep the muscle sample in a frozen state until arrival in the laboratory. Performance of a muscle biopsy for diagnostic purposes should be avoided in the ¢rst month of life, unless life -threatening events have occurred or reliable reference ranges are available for this age group. Medication should be avoided as much as possible before performing the biopsy to avoid false positive diagnosis due to secondary inhibitory e¡ects of medication (e.g. sodium valproate) or enhancement of subnormal enzyme activities leading to a false negative diagnosis (e.g. vitamins, coenzyme Q, etc.)
Biochemical approach to de nite diagnosis
After performance of the clinical and laboratory investigations, patients can be selected for further biochemical and molecular genetic investigations. Although the most reliable biochemical diagnostic approach consists of examination of a muscle biopsy because most of the defects are expressed in this tissue, 5 missed diagnoses can occur. This is because of tissue-speci¢c expression of some defects and because the absence of a respiratory chain defect in muscle does not completely exclude such a defect in other tissues (e.g. liver); this occurs rarely, however. A fresh muscle sample is preferable to a frozen muscle sample. Investigation of a fresh muscle biopsy, which contains functionally intact mitochondria, allows measurement of the overall capacity of the oxidative phosphorylation system. Moreover, the activities of the PDH complex and respiratory chain enzymes can subsequently be measured. If only a frozen muscle sample is available, only individual enzyme activities can be determined rather than the complete chain. A muscle biopsy can only be handled as a fresh sample if the specimen arrives in the diagnostic centre within 3 h of collection. In other cases, it should be frozen immediately in liquid nitrogen and sent to the diagnostic laboratory in dry ice. Table 3 summariz es the possible biochemical diagnostic procedures that are available for fresh and frozen muscle samples. In a fresh muscle sample, substrate oxidation rates of radiochemically labelled compounds ([1-14 C]pyruvate, [U-14 C]malate and [1,4-14 C]succinate) can be determined, or oxygen consumption rates from substrate oxidation can be measured. From these observations, preliminary conclusions can be drawn concerning where a defect in the respiratory chain may lie (e.g. in the PDH complex, the citric acid cycle, complex V or adenine nucleotide translocater). Measurement of the ATP+CrP production rate from substrates (e.g. pyruvate) is very important in establishing a defect in any of the above systems. The ultimate diagnosis can be made by measurement of the individual respiratory chain enzyme activities, complex Vand PDH complex. In a frozen muscle sample only individual enzyme activities can be determined, because the mitochondrial inner membrane is partially destroyed and, as a consequence, no information can be obtained concerning the overall oxidative phosphorylation capacity. Finally, in addition to the advantages described above, investigation of a fresh muscle sample is also preferred because, in our experience, in about 25% of patients in whom oxidation rates of substrates and ATP+CrP production rate are clearly reduced, no defect in complexes I-V and the PDH complex can be established. Thus, investigation of a frozen muscle sample alone leads to a false negative diagnosis in these patients.
The primary defect in patients with a clear disturbance in the oxidative capacity of the mitochondria, without a de¢ciency in any of the relevant complexes, remains to be elucidated. We are currently using proteomics technology in these patients in an attempt to identify the primary defect at the protein level.
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Investigation of broblasts
In some patients it is necessary to investigate ¢broblasts for diagnostic purposes. The indications for biochemical investigations in ¢broblasts are:
. If no muscle sample is available.
. If prenatal diagnosis is required.
. To clarify the results obtained in muscle tissue if no clear-cut diagnosis can be made. . If molecular-genetic investigations are required. . For research purposes.
Fibroblasts are less suitable than fresh muscle for investigating respiratory chain disorders, for the following reasons:
. A defect that is present in muscle is not always expressed in ¢broblasts. . Exclusion of a defect in ¢broblasts does not exclude the diagnosis with regard to muscle. . A speci¢c pattern of abnormalities demonstrated in ¢broblasts may not be re£ected in muscle tissue. . Enzyme de¢ciencies found in muscle are generally more pronounced than in ¢broblasts.
It is an absolute prerequisite to demonstrate a respiratory chain enzyme de¢ciency both in a muscle tissue and in ¢broblasts if prenatal diagnosis is required. In our opinion, if a defect is not expressed in ¢broblasts, a reliable prenatal diagnosis is not possible. In such cases, even investigation of chorionic villi or amniocytes in which the relevant enzyme appears to be present with a normal activity does not exclude the possibility that the fetus might, nevertheless, be a¡ected. Thus, if genetic counselling in a family with an a¡ected child is required, we strongly recommend performance of skin and muscle biopsies for diagnostic purposes.
Fibroblasts are also suitable for molecular-genetic analysis. For this reason, ¢broblasts should always be stored from every patient who might become a candidate for molecular-genetic studies. Finally, we recommend performance of a skin biopsy from every patient who is suspected of dying from a mitochondrial cytopathy because future diagnostic assays can be applied to subsequent relatives.
Until now, at least in our centre, diagnostic biochemical procedures in ¢broblasts have been restricted to determination of activities of respiratory chain enzymes and of the PDH complex activity.We are now developing assays enabling us to measure, in a comparable manner to muscle, the overall oxidative capacity of the mitochondria by measurement of the substrate oxidation rates and the production rate of ATP+CrP. In the very near future this method will be applied as a routine diagnostic approach, thus extending the diagnostic possibilities in ¢broblasts.
Prenatal diagnosis of respiratory chain defects
There is an increasing demand for prenatal diagnosis in families with a child who has been diagnosed with a respiratory chain defect. Prenatal diagnosis can only be performed reliably in families in which the index patient has been proven to su¡er from a multisystem disorder. This means that a defect has been proven in at least two di¡erent tissues. In most cases, muscle and ¢broblasts are the tissues of choice. If a defect is not expressed in ¢broblasts, prenatal diagnosis is not possible at the moment. Development of new diagnostic tests (e.g. measurement of overall oxidative capacity of mitochondria in ¢broblasts or application of proteomics) may lead to increased prenatal diagnostic possibilities. A further prerequisite for performance of prenatal diagnosis is the absence of a mitochondrial DNA mutation in the a¡ected child. In the presence of such a mutation, performance of reliable prenatal diagnosis is nearly impossible because the percentage of heteroplasmy in a certain patient may vary considerably between the various tissues such as muscle, blood and ¢broblasts. This means that the ¢nding of a normal activity of the speci¢c enzyme in the chorionic villi does not exclude a de¢ciency of the enzyme in other fetal cells. Therefore, mitochondrial DNA mutations have to be excluded in the index case before considering prenatal diagnosis. 6 However, this limitation excludes prenatal diagnosis in only a relatively small number of families because mitochondrial DNA mutations occur only rarely. We are able to perform prenatal diagnosis in families with a proven de¢ciency of complex I and/or complex IV and of the PDH complex. In the very near future we will be able to also include complex II de¢ciency in our prenatal diagnostic programme. Prenatal diagnosis of the above defects can be performed both in chorionic villi and in amniocytes. We prefer examination of native chorionic villi because the prenatal diagnosis can be performed at a considerably earlier stage of the pregnancy (around the 10th week) as compared with amniocytes. Moreover, chorionic villi can be investigated without cultivation of the cells, in contrast to amniocytes. This reduces the time of investigation of the prenatal diagnostic procedure considerably. Clearly, prenatal diagnosis can only be performed in fetal cells that are not contaminated with maternal cells. Until recently we performed prenatal diagnosis only by measurement of the activities of the individual enzyme complexes. 6 At the moment we are also able to perform prenatal diagnosis by mutation analysis in cases where the defect has been characterized at the nuclear DNA level. At present we perform prenatal DNA analysis in families with established mutation(s) in nuclear genes of complex I, 7 the E1a gene of the PDH complex and the SURF-1 gene of cytochrome oxidase. This approach can also be applied to other nuclear genes responsible for OXPHOS de¢ciencies. In our institute, prenatal diagnosis is restricted to families in which a speci¢c defect has been detected in muscle and ¢broblasts of at least one patient in that family or in families in which the genetic defect in the nuclear DNA has been established.
An important feature in the ¢nal interpretation of the biochemical measurements concerns the observed residual activity of the de¢cient enzyme(s). An important question is: has an enzyme de¢ciency associated with a relatively high residual activity any pathological signi¢cance? In our view, the answer to this question can be deduced from our results obtained in ¢broblasts. For example, we detected a complex I de¢ciency in ¢broblasts in 55 patients. The residual complex I activity varied between 18% and 89% of the lowest control value. In13 of these patients a mutation was found in one of the nuclear encoded subunits of complex I. The residual complex I activity varied in these patients from 32% to 82%. This means that, at least in ¢broblasts, patients with a proven mutation in a nuclear encoded complex I gene may exhibit a relatively high residual enzyme activity, even exceeding 80%. The same holds for prenatal diagnostic investigations. We made a prenatal diagnosis in 23 pregnancies in 15 families in which complex I de¢ciency was established. In four of these pregnancies complex I activity was reduced in chorionic villi. The residual activity in these latter cases varied between 30% and 81%. Two of these pregnancies were continued and in both cases a severe complex I de¢ciency was found in the newborn child. The complex I activity in the chorionic villi of these two pregnancies showed a relatively high residual activity of 75% and 81% of the lowest control value, respectively. Thus, it can be concluded that, at least for complex I, high residual activity found in chorionic villi should be considered as pathological for the unborn child.
Conclusion
Much progress has been made in the biochemical diagnosis of mitochondrial respiratory chain defects. The postnatal diagnosis of these defects should preferably be performed in a fresh muscle sample. Practical guidelines have been presented for optimal performance of a reliable diagnostic approach. Attention has been paid to the prenatal diagnostic possibilities of respiratory chain disorders. The increasing demand for prenatal diagnosis of these disorders prompted us to evaluate the present and future biochemical and molecular-genetic possibilities.
